Education
About Us
Working with TipRanks
Follow Us
Q-linea AB (DE:3F80)
FRANKFURT:3F80
3F80 Stock Chart & Stats
€2.24
--
Market closed
€2.24
--
Day’s Range― - ―
52-Week Range€1.87 - €40.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.00
Market Cap
€43.22M
Enterprise Value-€88.56M
Total Cash (Recent Filing)€258.11M
Total Debt (Recent Filing)€7.71M
Price to Earnings (P/E)―
Beta84.66
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding18,949,081
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Q-linea AB News
3F80 FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was €1.87 and its highest was €40.99 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is €43.22M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Apr 30, 2026 which is in 76 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Feb 04, 2026. The company reported -€0.354 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.354.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -€0.354 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.962%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in DE:3F80
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―